The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Ticovac Market Become By 2030 Compared To 2026?
The ticovac market size has experienced considerable expansion recently. It is projected to increase from $4.31 million in 2025 to $4.63 million in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. This historical growth stems from the endemic presence of tick-borne encephalitis, public health vaccination initiatives, growing outdoor activity exposure, hospital-based immunization programs, and regulatory approvals for TBE vaccines.
The ticovac market is projected to experience substantial expansion over the upcoming years, with an anticipated growth to $6.11 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period is largely attributable to factors such as the expansion of vaccination coverage across Europe, an increase in travel to endemic regions, a rise in climate-driven tick populations, the implementation of stronger preventive healthcare policies, and greater investment in vaccine infrastructure. Significant trends expected in this period include an increasing demand for tick-borne disease vaccination, the broadening of preventive travel immunization, the development of government-led vaccination programs, enhanced awareness of vector-borne diseases, and improvements in cold chain vaccine distribution.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19939&type=smp
Which Core Factors Are Supporting The Expansion Of The Ticovac Market?
The expanding occurrence of tick-borne illnesses is projected to fuel the expansion of the ticovac market in the coming years. These diseases are human ailments passed on via bites from infected ticks, originating from bacteria, viruses, or parasites. The increase in tick-borne diseases is attributed to shifts in climate, the proliferation of tick habitats, greater human interaction with affected areas, and improved diagnostic capabilities. Ticovac is essential for addressing tick-borne diseases, offering active immunization against tick-borne encephalitis (TBE), a severe viral infection transmitted by tick bites. For example, in February 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that the total incidence of Lyme disease reached 18.9 cases per 100,000 population, marking a rate 68.8% higher than in preceding years. Within areas of high incidence, the median rate saw a 58% increase, reaching 68.3 cases per 100,000, whereas for children aged 5–9 years, the incidence was 16.5 cases per 100,000, showing an 11.5% rise. Consequently, the growing prevalence of tick-borne diseases is propelling the growth of the ticovac market.
How Is The Ticovac Market Structured Across Different Market Segments?
The ticovac market covered in this report is segmented –
1) By Formulation: Inactivated Vaccines, Live Attenuated Vaccines
2) By Indication: Tick-Borne Encephalitis, Japanese Encephalitis, Rabies Encephalitis
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
What Trends Are Affecting The Ticovac Market Dynamics?
Companies operating in the ticovac market are concentrating on developing innovative formulations such as suspension liquid to gain a competitive advantage within the industry. Suspension liquid is a vaccine designed to prevent tick-borne encephalitis, delivered through intramuscular injection. It comes in a 0.5 mL dose and is suitable for both adult and pediatric patients. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical manufacturer, launched Ticovac, a vaccine aimed at preventing tick-borne encephalitis (TBE), which is a viral infection affecting the brain and spinal cord. This vaccine is the first of its kind in Japan, providing protection against the disease in prevalent regions. The vaccine is available in two versions, one for adults and one for children, both administered as a 0.5 mL intramuscular injection.
Who Are The Companies Shaping The Ticovac Market Landscape?
Major companies operating in the ticovac market are Pfizer Inc.
Access The Complete Ticovac Market Report:
https://www.thebusinessresearchcompany.com/report/ticovac-global-market-report-
Which Area Represents The Largest Portion Of The Ticovac Market?
Europe was the largest region in the ticovac market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the ticovac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model